UNSPSC 51102868: Nystatin/triamcinolone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102868 Nystatin/triamcinolone, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally covers a specific pharmaceutical combination product, but the recent opportunities tagged under it involve naloxone, drug deactivation systems, fire rescue medical supplies, and multi-source generic pharmaceuticals and OTC products—none of which fall within the nystatin/triamcinolone scope. State and local purchasing offices appear to be using this code inconsistently or as a catch-all pharmaceutical tag rather than for the specific antifungal-steroid combination the code describes. The mismatch between the code's narrowly defined commodity and the broad-spectrum pharmaceutical solicitations tagged under it suggests that tracking demand specifically for nystatin/triamcinolone through this UNSPSC code will not yield actionable purchasing signals.

The issuing bodies in the recent opportunities span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal procurement offices (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). Geographic activity is concentrated in Florida, Texas, and Minnesota, with broader multistate reach through the MMCAP cooperative. If nystatin/triamcinolone demand exists in state and local procurement, it is either tagged under different UNSPSC codes or buried within larger pharmaceutical framework agreements—the code itself does not yield usable market intelligence for vendors targeting combination-antifungal opportunities at the state and local level.